Cancer of the Prostate

Roach, Mack; Wallner, Kent E.; Hsu, I‐Chow; Carroll, Peter R.

doi:10.1016/b978-1-4160-5897-7.00046-9

Cited by 2 publications

(1 citation statement)

References 512 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rationale for pelvic nodal irradiation includes: (1) prostate cancer is a radiosensitive tumor: (2) populations can be defined who are at risk for lymph node involvement (LNI); (3) and there are clinical data supporting the improved outcomes with prophylactic radiotherapy (see Table II) 124. For example, the four‐armed randomized RTOG 9413 trial specifically addressed the value of radiotherapeutic treatment of the pelvic nodes in high‐risk prostate cancer and the updated results favor pelvic lymph node treatment in combination with hormonal ablation therapy 119, 125, 126.…”

Section: Introduction To Spect/ct/pet Ultrasound Imaging—general Conmentioning

confidence: 99%

Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions

Roach

Albérini

Pecking

et al. 2011

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

As cancer treatment cost soar and the mantra for "personalized medicine" grows louder, we will increasingly be searching for solutions to these diametrically opposed forces. In this review we highlight several exciting novel imaging strategies including MRI, CT, PET SPECT, sentinel node, and ultrasound imaging that hold great promise for improving outcomes through detection of lymph node involvement. We provide clinical data that demonstrate how these evolving strategies have the potential to transform treatment paradigms.

show abstract

Section: Introduction To Spect/ct/pet Ultrasound Imaging—general Conmentioning

confidence: 99%

Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions

Roach

Albérini

Pecking

et al. 2011

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate‐risk, high‐risk, localized, and locally advanced prostate cancer

Roach

2014

Cancer

Self Cite

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is now a well‐established standard of care in combination with definitive radiotherapy for patients with unfavorable intermediate‐risk to high‐risk locally advanced prostate cancer. It is also well established that combination modality treatment with ADT and radiotherapy is superior to either of these modalities alone for the treatment of patients with high‐risk locally advanced disease. Current treatment guidelines for prostate cancer in the United States are based on the estimated risk of recurrence and death. This review examines the clinical evidence underpinning the use of ADT and radiotherapy among patients with high‐risk localized and locally advanced disease in the United States. This review also considers the rationale for moving from traditional luteinizing hormone‐releasing hormone agonists to more recently developed gonadotrophin‐releasing hormone antagonists. Cancer 2014;120:1620–1629. © 2014 American Cancer Society.

show abstract

Cancer of the Prostate

Cited by 2 publications

References 512 publications

Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions

Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions

Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate‐risk, high‐risk, localized, and locally advanced prostate cancer

Contact Info

Product

Resources

About